Arden Trust’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,182
| Closed | -$306K | – | 244 |
|
|
2024
Q1 | $306K | Sell |
4,182
-456
| -10% | -$35.1K | 0.04% | 197 |
|
|
2023
Q4 | $376K | Buy |
4,638
+465
| +11% | +$36.2K | 0.06% | 173 |
|
|
2023
Q3 | $313K | Buy |
4,173
+900
| +27% | +$69.2K | 0.05% | 183 |
|
|
2023
Q2 | $253K | Sell |
3,273
-962
| -23% | -$76.7K | 0.04% | 213 |
|
|
2023
Q1 | $352K | Sell |
4,235
-2,062
| -33% | -$171K | 0.06% | 225 |
|
|
2022
Q4 | $541K | Sell |
6,297
-446
| -7% | -$35.3K | 0.11% | 165 |
|
|
2022
Q3 | $416K | Hold |
6,743
| – | – | 0.11% | 180 |
|
|
2022
Q2 | $417K | Buy |
6,743
+462
| +7% | +$28.6K | 0.1% | 189 |
|
|
2022
Q1 | $373K | Sell |
6,281
-509
| -7% | -$32.5K | 0.07% | 204 |
|
|
2021
Q4 | $493K | Buy |
6,790
+1,010
| +17% | +$69.6K | 0.08% | 199 |
|
|
2021
Q3 | $404K | Sell |
5,780
-238
| -4% | -$16.7K | 0.07% | 216 |
|
|
2021
Q2 | $414K | Sell |
6,018
-45
| -0.7% | -$3K | 0.07% | 219 |
|
|
2021
Q1 | $392K | Buy |
+6,063
| New | +$391K | 0.07% | 232 |
|
|
2020
Q2 | – | Sell |
-3,110
| Closed | -$233K | – | 494 |
|
|
2020
Q1 | $233K | Sell |
3,110
-218
| -7% | -$15.1K | 0.05% | 256 |
|
|
2019
Q4 | $216K | Sell |
3,328
-1
| -0% | -$65 | 0.03% | 320 |
|
|
2019
Q3 | $211K | Buy |
+3,329
| New | +$218K | 0.03% | 337 |
|
|
2019
Q2 | – | Sell |
-3,378
| Closed | -$220K | – | 363 |
|
|
2019
Q1 | $220K | Sell |
3,378
-11
| -0.3% | -$731 | 0.04% | 344 |
|
|
2018
Q4 | $212K | Buy |
3,389
+540
| +19% | +$37.7K | 0.04% | 306 |
|
|
2018
Q3 | $220K | Sell |
2,849
-2,669
| -48% | -$202K | 0.03% | 341 |
|
|
2018
Q2 | $391K | Sell |
5,518
-592
| -10% | -$41.8K | 0.06% | 252 |
|
|
2018
Q1 | $460K | Sell |
6,110
-162
| -3% | -$12.9K | 0.07% | 231 |
|
|
2017
Q4 | $450K | Buy |
6,272
+64
| +1% | +$4.86K | 0.07% | 228 |
|
|
2017
Q3 | $503K | Sell |
6,208
-1,041
| -14% | -$79.6K | 0.08% | 230 |
|
|
2017
Q2 | $513K | Sell |
7,249
-650
| -8% | -$43.3K | 0.08% | 232 |
|
|
2017
Q1 | $536K | Sell |
7,899
-230
| -3% | -$16.2K | 0.08% | 217 |
|
|
2016
Q4 | $582K | Sell |
8,129
-595
| -7% | -$44.2K | 0.09% | 211 |
|
|
2016
Q3 | $690K | Sell |
8,724
-27,092
| -76% | -$2.2M | 0.11% | 174 |
|
|
2016
Q2 | $2.99K | Buy |
35,816
+200
| +0.6% | +$17.7K | 0.23% | 101 |
|
|
2016
Q1 | $3.27M | Buy |
35,616
+1,598
| +5% | +$144K | 0.26% | 89 |
|
|
2015
Q4 | $3.44M | Buy |
34,018
+1,726
| +5% | +$180K | 0.29% | 83 |
|
|
2015
Q3 | $3.17M | Buy |
32,292
+17,320
| +116% | +$1.92M | 0.26% | 97 |
|
|
2015
Q2 | $1.75K | Buy |
14,972
+1,825
| +14% | +$199K | 0.26% | 100 |
|
|
2015
Q1 | $1.29K | Buy |
13,147
+7,832
| +147% | +$795K | 0.19% | 141 |
|
|
2014
Q4 | $501K | Sell |
5,315
-124
| -2% | -$12.8K | 0.07% | 239 |
|
|
2014
Q3 | $579K | Buy |
5,439
+88
| +2% | +$8.62K | 0.08% | 219 |
|
|
2014
Q2 | $443K | Buy |
5,351
+190
| +4% | +$14.8K | 0.06% | 226 |
|
|
2014
Q1 | $366K | Sell |
5,161
-252
| -5% | -$19.8K | 0.05% | 259 |
|
|
2013
Q4 | $406K | Buy |
5,413
+519
| +11% | +$36.1K | 0.05% | 236 |
|
|
2013
Q3 | $307K | Sell |
4,894
-279
| -5% | -$16.7K | 0.04% | 255 |
|
|
2013
Q2 | $265K | Buy |
+5,173
| New | +$270K | 0.03% | 274 |
|
Other funds holding GILD
Arden Trust's GILD Position: Q2 2024 in Review
Arden Trust sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 4,182 shares — an estimated $306K sold.
Arden Trust first reported a position in GILD in Q2 2013 and held it in 40 quarters. The position peaked at $3.44M in Q4 2015. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Arden Trust reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
- Arden Trust sold 4,182 Gilead Sciences shares in Q2 2024, an estimated $306K.
- Arden Trust first reported a position in Gilead Sciences in Q2 2013 and held it in 40 quarters.
- Arden Trust's Gilead Sciences position peaked at $3.44M in Q4 2015.
- 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Arden Trust's 13F filing for Q2 2024, filed 9 Jul 2024.